Goldman Sachs added Cintas to the firm’s Conviction List and keeps a Buy rating on the shares with a $592 price target. The company’s organic growth has structurally reset higher than pre-Covid levels, rising to 7%-8% from 6%-7% previously, driven by volumes and an expanded opportunity in delivering uniforms into the healthcare vertical as well as ongoing penetration of the unvended market, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CTAS: